Cantillon Capital Management LLC Has $176.42 Million Stock Holdings in Zoetis Inc. $ZTS

Cantillon Capital Management LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,205,716 shares of the company’s stock after selling 13,379 shares during the period. Cantillon Capital Management LLC’s holdings in Zoetis were worth $176,420,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Savvy Advisors Inc. increased its stake in shares of Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after purchasing an additional 1,114 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock worth $67,000 after purchasing an additional 152 shares in the last quarter. Chicago Partners Investment Group LLC increased its position in Zoetis by 67.0% during the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after buying an additional 1,961 shares during the last quarter. QRG Capital Management Inc. raised its holdings in Zoetis by 4.9% during the second quarter. QRG Capital Management Inc. now owns 77,741 shares of the company’s stock valued at $12,124,000 after buying an additional 3,616 shares in the last quarter. Finally, Consolidated Investment Group LLC raised its holdings in Zoetis by 59.6% during the second quarter. Consolidated Investment Group LLC now owns 26,235 shares of the company’s stock valued at $4,091,000 after buying an additional 9,800 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down previously from $190.00) on shares of Zoetis in a report on Thursday. Weiss Ratings raised shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 13th. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Down 0.6%

ZTS opened at $124.35 on Friday. The business has a 50 day moving average of $123.51 and a 200-day moving average of $138.66. The stock has a market capitalization of $54.80 billion, a price-to-earnings ratio of 20.93, a P/E/G ratio of 2.17 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.40.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio is presently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.